Tenaya Therapeutics - שווי פירמה כולל TNYA

Tenaya Therapeutics (TNYA) is developing long-term gene correction methods for cardiac pathologies, leveraging unique intellectual property and innovative therapies for hereditary cardiomyopathies to drive future sales to clinics. Historical price action on the GURU.Markets platform shows an Enterprise Value of 9.61, while the company's strategy focuses on early-stage trials of key molecules and maintaining high capital liquidity.

Enterprise value combines market capitalization and net debt, determining the actual cost of a full business buyout while accounting for liquid assets. Enterprise value modeling clearly demonstrates the investment attractiveness of Tenaya Therapeutics (TNYA), whose valuation depends directly on the value of its own gene therapy production capacities for treating rare cardiovascular pathologies.